Stem Cell Therapy for Traumatic Brain Injury

What This Article Covers

Traumatic brain injury (TBI) can cause lasting motor, cognitive, and sensory deficits that current medicine has few tools to reverse. Stem cell therapy — using cells like mesenchymal stromal cells or a patient's own bone marrow cells — is being studied as a way to help the injured brain repair itself. This article covers how these therapies are thought to work, what the strongest published clinical evidence actually shows, and who might realistically be a candidate for a clinical trial today.

How It's Thought to Work

Stem cell therapies for TBI generally don't aim to replace lost neurons directly. Instead, researchers believe the transplanted cells — whether lab-processed mesenchymal stromal cells (as in SanBio's SB623) or a patient's own bone marrow mononuclear cells — act more like biological signaling stations. They're thought to reduce inflammation, encourage the brain's own repair circuitry, support blood vessel and white-matter integrity, and possibly help form new neural connections near the injury site. In several trials, cells are delivered either by a targeted stereotactic injection into brain tissue near the damaged area or by intravenous infusion in the days after injury.

What the Evidence Shows

The most rigorous data comes from SanBio's STEMTRA Phase 2 trial, a randomized, sham-surgery-controlled study of 61 adults with chronic motor deficits from moderate-to-severe TBI, published in Neurology. The results were genuinely encouraging: patients who received a stereotactic injection of SB623 cells improved by an average of 8.3 points on the Fugl-Meyer Motor Scale at 24 weeks, compared to just 2.3 points in the sham-surgery control group — a statistically significant difference (P = .04). Improvements also extended to gait speed, dexterity, and disability scores, and the treatment was reported as well tolerated with no new safety signals. A 2024 post hoc analysis of the same trial data, published in Neurology, further examined which patient subgroups responded best.

Separately, researchers at UTHealth Houston, led by Dr. Charles Cox, have studied a patient's own bone marrow mononuclear cells rather than lab-grown cells. A Phase II, double-blind, placebo-controlled trial in 47 children with severe TBI (published in Brain, January 2024) found the approach safe and feasible when cells were harvested and infused within 48 hours of injury, with treated children showing better white matter preservation and reduced cerebral atrophy compared to typical outcomes. An earlier Phase I/IIa trial in adults (Stem Cells, 2017) also reported no serious treatment-related adverse events and preserved white matter integrity, though that study was small (25 patients), non-randomized, and is considered hypothesis-generating rather than definitive.

Taken together, these are real, peer-reviewed signals of benefit — not just preclinical promise. But every trial to date has been Phase 1 or Phase 2, involved small patient numbers, and none has yet been confirmed in a completed Phase 3 study, which is the bar regulators require before approval.

Who Might Be a Candidate

• Adults with chronic motor deficits from a moderate-to-severe TBI who are enrolled in an active, IRB-approved clinical trial (such as follow-on studies to STEMTRA)
• Children or adults with severe acute TBI being treated at a research center running an approved bone-marrow-cell protocol, such as UTHealth Houston's program
• Patients who are past the acute emergency phase and have a stable, well-characterized injury on imaging (many trials require visible encephalomalacia or similar findings)
• People who understand this is investigational — not a standard-of-care treatment available at typical clinics
• Anyone considering this should be wary of direct-to-consumer stem cell clinics offering unproven “TBI stem cell treatments” outside of registered clinical trials, which the FDA has repeatedly warned carry real risks with no proven benefit

Bottom Line

Stem cell therapy for traumatic brain injury is one of the more genuinely promising areas of regenerative neuroscience, backed by a statistically significant, peer-reviewed Phase 2 result and consistent safety signals across multiple independent research groups. That's real progress. But “promising Phase 2 data” is not the same as “proven treatment” — no stem cell therapy is FDA-approved for TBI, larger confirmatory trials are still needed, and access today is limited to legitimate research studies, not commercial clinics.